On March 3 2026, we received a piece of good news: the Nectin4-targeted ADC project, LNF2105 for injection, jointly developed by Lunan Pharmaceutical and supported by Adcoris' platform technology, officially received the clinical trial approval notice from the National Medical Products Administration (NMPA), acceptance number: CXSL2501107. This is not only an important achievement since the establishment of the technological cooperation between the two parties, but also an authoritative validation of Adcoris' core technology platform capabilities.
Lunan Pharmaceutical is a large comprehensive pharmaceutical group integrating the production, research and development, and sales of traditional Chinese medicine, chemical drugs, and biological products, possessing independently developed specific antibodies targeting Nectin4, FGFR2b, and related intellectual property rights. In the R&D of this project, Lunan Pharmaceutical provided highly specific Nectin-4 antibodies; Adcoris relied on its proprietary ADC technology platform, including a full set of technologies such as highly potent cytotoxins (Drug), cleavable linkers (Linker), and precise conjugation technology, to jointly complete the design and development of this innovative ADC drug. This project is also Adcoris' first domestic collaborative ADC project.
In addition to the LNF2105 for injectable , Adcoris also has two clinical-stage pipelines, ADC2122 and ADC2154, which are progressing smoothly in clinical trials. These achievements validate that the ADC molecules developed using Adcoris' technology platform possess excellent druggability and have earned recognition from regulatory authorities and partners for Adcoris' ADC technology.
In the future, Adcoris will continue to focus on developing first-in-class (FIC) and best-in-class (BIC) ADC/AXC products. We welcome collaboration with industry investment institutions and pharmaceutical companies to translate our technological advantages into high-quality innovative drugs with clinical differentiation and commercial competitiveness.